The short answer
Whether a multivitamin affects bictegravir depends mainly on its mineral ingredients and how it is taken. Calcium and iron products may be taken with Biktarvy together with food, while other mineral combinations need a separate timing check. There is no single measured interaction that applies to every multivitamin or prenatal product.
What this answer covers
Adult oral Biktarvy and multivitamin products, especially those containing calcium, iron, magnesium, aluminum or zinc. Evidence is ingredient-specific; vitamin-only products and every commercial mixture were not directly tested.
- Supplement or preparation
- Multivitamin
- Medication ingredient
- bictegravir
Which ingredients matter?
A product called a multivitamin may contain vitamins alone or a mixture of vitamins and minerals. Minerals such as calcium, iron and magnesium can bind bictegravir in the digestive tract. The product name, including “prenatal,” does not tell you which instructions apply. Read the complete ingredients and amounts, and remember that an additional magnesium tablet or antacid also contributes to the daily schedule.
What evidence supports the concern?
Direct research found lower bictegravir exposure with fasting calcium carbonate, ferrous fumarate and a combined aluminum/magnesium antacid. Taking calcium or iron with food reduced the practical concern, and current labeling allows that approach. Researchers did not test every multivitamin mixture. The drug-concentration changes from an individual mineral study should therefore not be presented as a proven percentage reduction for your multivitamin.
Can I take a prenatal vitamin at the same time?
Biktarvy labeling permits calcium and iron products together with food and gives explicit fasting separation instructions during pregnancy. A prenatal product may contain additional minerals, so the whole formulation still needs review. Do not assume that because its iron ingredient can be taken with food, every other ingredient has been studied under the same conditions. Your HIV pharmacist can reconcile the prenatal plan with the HIV regimen.
How should I choose a daily schedule?
Bring a photo of the supplement facts panel and list all mineral supplements, laxatives and antacids you use. A pharmacist can identify a meal-based option or an appropriate separation schedule for the actual ingredients. Continue Biktarvy as prescribed rather than skipping it around supplements. If a product has no relevant minerals, a mineral-binding warning should not be automatically applied simply because it is sold as a multivitamin.
Evidence and practical considerations
Absorption & effectiveness
Whether a multivitamin affects bictegravir depends mainly on its mineral ingredients and how it is taken. Calcium and iron products may be taken with Biktarvy together with food, while other mineral combinations need a separate timing check. There is no single measured interaction that applies to every multivitamin or prenatal product.
- Exact scope
- Adult oral Biktarvy and multivitamin products, especially those containing calcium, iron, magnesium, aluminum or zinc. Evidence is ingredient-specific; vitamin-only products and every commercial mixture were not directly tested. with Adult oral bictegravir as Biktarvy 50/200/25 mg fixed combination
- Medication form and route
- Adult oral bictegravir as Biktarvy 50/200/25 mg fixed combination; oral mineral, supplement or antacid within stated preparation scope
- Timing or duration
- Evidence comes from single-dose individual-mineral/combined-antacid studies and current guidance, not a trial of every daily multivitamin product.
What remains uncertain
- Mineral composition, dose and food determine applicability. The interaction magnitude for multivitamins is not established; results from calcium carbonate or ferrous fumarate alone do not fully describe a complex mixture.
Factors that may matter: Exact mineral ingredients, preparation and elemental amount; Biktarvy fixed-combination formulation; Food and direction of administration when applicable; Concurrent mineral products, adherence and viral-load monitoring.
Read the supporting source summaries
Source 1: current U.S. regulatory prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People using the fixed combination Biktarvy for HIV treatment; adult-strength tablets contain bictegravir 50 mg, emtricitabine 200 mg and tenofovir alafenamide 25 mg.
Give Biktarvy at least 2 hours before or 6 hours after aluminum/magnesium antacids. Calcium or iron can be taken together with food; routine simultaneous fasting administration or Biktarvy 2 hours after calcium/iron is not recommended. St. John’s wort coadministration is not recommended because bictegravir and tenofovir alafenamide may decrease.
How this applies: Exact bictegravir active ingredient is bridged from bictegravir sodium by the label’s declared equivalent dose. Cation findings concern bictegravir; St. John’s wort can also affect the tenofovir alafenamide component. No emtricitabine interaction is inferred. Exact article scope: Adult oral Biktarvy and multivitamin products, especially those containing calcium, iron, magnesium, aluminum or zinc. Evidence is ingredient-specific; vitamin-only products and every commercial mixture were not directly tested.
Combination-product labeling, not evidence for bictegravir monotherapy. Named antacid directions are not direct experiments on every nutritional magnesium/aluminum formulation. The label supplies no echinacea trial or measured interaction for every multivitamin. Pregnancy has explicit additional fasting instructions.
Source 2: U.S. expert clinical treatment guideline
clinicalinfo.hiv.gov · Source check Sep 10, 2026
Population: Adults and adolescents receiving integrase inhibitor regimens for HIV.
Bictegravir mineral directions depend on cation and food. If raltegravir must be used with polyvalent mineral supplements, give it at least 2 hours before or 6 hours after and monitor virologic response. Multivitamin chelation magnitude is uncertain. Raltegravir antacid rules are separate: avoid Al/Mg, and distinguish calcium carbonate 400 mg twice daily from 1,200 mg once daily. Do not coadminister bictegravir with St. John’s wort.
How this applies: Exact-drug management guidance. Bictegravir sodium and raltegravir potassium are interpreted through their labels’ active-moiety equivalents. Calcium/iron food exceptions for bictegravir do not transfer to raltegravir. Exact article scope: Adult oral Biktarvy and multivitamin products, especially those containing calcium, iron, magnesium, aluminum or zinc. Evidence is ingredient-specific; vitamin-only products and every commercial mixture were not directly tested.
Expert recommendations include predicted interactions where exact-pair clinical studies are absent. A suggested supplement schedule does not supersede the distinct antacid avoidance instructions. No universal safe dose or virologic risk percentage is established.
Source 3: peer-reviewed prospective human pharmacokinetic study
europepmc.org · Source check Sep 10, 2026
Population: 42 healthy HIV-negative adults aged 18-45 years, in three cohorts of 14; open-label single-dose study conducted in 2016.
Fasted simultaneous bictegravir exposure was lower by 79% with combined Al/Mg antacid, 33% with calcium carbonate and 63% with ferrous fumarate. Bictegravir 2 hours before Al/Mg largely preserved exposure; 2 hours after still reduced it by 52%. With food, calcium exposure ratio was 1.033 and iron ratio 0.838 relative to bictegravir alone fasting; Al/Mg still reduced exposure by 47%.
How this applies: Direct preparation-specific evidence for adult oral bictegravir in Biktarvy. Calcium carbonate and ferrous fumarate findings are explicitly bounded within broader calcium and iron articles. These data do not directly measure every multivitamin, magnesium chelate or aluminum product. Exact article scope: Adult oral Biktarvy and multivitamin products, especially those containing calcium, iron, magnesium, aluminum or zinc. Evidence is ingredient-specific; vitamin-only products and every commercial mixture were not directly tested.
Single doses in healthy people, not a clinical failure trial. Combined Al/Mg does not isolate either ion. Fed combination arms were compared with a fasted-alone reference, not fed-alone control. Sponsor Gilead participated in design, analysis and writing. Discussion language about regional timing differs from the current U.S. label; the U.S. 2-before/6-after antacid instructions govern the article.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Current exact-drug labeling and guidance checked; original human studies and neutral findings assessed. Current statements adjudicated with formulation, food and directional timing corrections. Article written; clinical sign-off not recorded. | |
| Research summary published |
Article revision: 21b1ab7270d6155d
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.